Eli Buchbinder
University of Haifa
PsychologyMelanomaDomestic violenceMedicineSocial psychology
What is this?
Publications 133
#1Shilpa Grover (Harvard University)H-Index: 10
#2Michael Dougan (Harvard University)H-Index: 17
Last. Alex B. Ruan (Harvard University)H-Index: 1
view all 21 authors...
BACKGROUND There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis. METHODS We performed a retrospective analysis of melanoma patients at Dana-Farber Cancer Institute who received PD-1, CTLA-4, or combination ICIs between May 2011 to October 2017. Clinical and laboratory characteristics associated with pathologically confi...
#1James SunH-Index: 24
#2Brian R. Gastman (Cleveland Clinic)H-Index: 25
Last. Anupam Desai (BIDMC: Beth Israel Deaconess Medical Center)
view all 14 authors...
This article analyzes the narratives of survivors of father−daughter incest using 20 in-depth interviews with women, each asked to choose a title for her life-story and reflect on its meaning. Thre...
#1Eli Buchbinder (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 26
#2Justine V. Cohen (Harvard University)H-Index: 13
Last. Ryan J. Sullivan (Harvard University)H-Index: 42
view all 8 authors...
#1Meghan J. Mooradian (Harvard University)H-Index: 4
#2James M. Cleary (Harvard University)H-Index: 27
Last. Keiran S.M. SmalleyH-Index: 33
view all 16 authors...
#1Sapna Pradyuman Patel (University of Texas MD Anderson Cancer Center)H-Index: 20
#2Megan Othus (Fred Hutchinson Cancer Research Center)H-Index: 31
Last. Larissa A. KordeH-Index: 23
view all 13 authors...
#1Shilpa Grover (Harvard University)H-Index: 10
#2Alex B. Ruan (Harvard University)H-Index: 1
Last. Mark M. Awad (Harvard University)H-Index: 38
view all 12 authors...
PURPOSE:Enterocolitis is among the leading adverse events associated with immune checkpoint inhibitors (ICIs). There are limited retrospective data regarding the safety of ICIs in patients with inf...
#1Shilpa GroverH-Index: 10
Last. Kenneth L. KehlH-Index: 6
view all 12 authors...
#1Diana D. Shi (Brigham and Women's Hospital)H-Index: 5
#1Diana D. Shi (Brigham and Women's Hospital)
Last. Ayal A. Aizer (Brigham and Women's Hospital)H-Index: 27
view all 9 authors...
Abstract Background The use of targeted therapies and immune checkpoint inhibitors has drastically changed the management of patients with melanoma and brain metastases. Specifically, combination therapy with ipilimumab, a cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor, and nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, has become a preferred systemic therapy option for patients with melanoma and asymptomatic brain metastases. However, the efficacy and toxicity profile of th...